Cargando…
36‐month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease
INTRODUCTION: The LipiDiDiet trial investigates the effects of the specific multinutrient combination Fortasyn Connect on cognition and related measures in prodromal Alzheimer's disease (AD). Based on previous results we hypothesized that benefits increase with long‐term intervention. METHODS:...
Autores principales: | Soininen, Hilkka, Solomon, Alina, Visser, Pieter Jelle, Hendrix, Suzanne B, Blennow, Kaj, Kivipelto, Miia, Hartmann, Tobias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821311/ https://www.ncbi.nlm.nih.gov/pubmed/32920957 http://dx.doi.org/10.1002/alz.12172 |
Ejemplares similares
-
24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial
por: Soininen, Hilkka, et al.
Publicado: (2017) -
Research diagnostic criteria for Alzheimer’s disease: findings from the LipiDiDiet randomized controlled trial
por: Rosenberg, Anna, et al.
Publicado: (2021) -
The LipiDiDiet trial: what does it add to the current evidence for Fortasyn Connect in early Alzheimer’s disease?
por: Rasmussen, Jill
Publicado: (2019) -
A competing risk joint model for dealing with different types of missing data in an intervention trial in prodromal Alzheimer’s disease
por: van Oudenhoven, Floor M., et al.
Publicado: (2021) -
Correction: A competing risk joint model for dealing with different types of missing data in an intervention trial in prodromal Alzheimer’s disease
por: van Oudenhoven, Floor M., et al.
Publicado: (2023)